IGF-1 LR3

A Natural Experiment in Absent IGF-1

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Laron syndrome is a congenital condition in which growth hormone receptor defects prevent normal IGF-1 production. Laron and Werner reported in Endocrine-Related Cancer in 2023 that patients with the syndrome do not develop cancer, describing it as of major scientific and translational relevance.

Key facts

Cause
Growth hormone receptor defect
Consequence
Congenital IGF-1 deficiency
Reported observation
Patients do not develop cancer
2023 paper
Laron & Werner (PMID 37343154)
Journal
Endocr Relat Cancer
Historical account
Laron 2021 (PMID 32964395)
Follow-up work
Genome-wide profiling of patient cells

What the condition is

Growth hormone is produced normally, but its receptor does not function, so the signal cannot be received. Since the liver produces IGF-1 in response to that signal, the result is high circulating growth hormone alongside very low IGF-1. This unusual combination separates the two arms of the axis in a way no experiment could deliberately arrange.

Why it is a natural experiment

Deliberately removing IGF-1 from humans for decades is not something anyone could do. A congenital condition does it, and the affected individuals can be followed across a lifetime. That is the only route to observing what lifelong absence of a signalling axis produces, and it is why rare genetic conditions carry evidential weight out of proportion to how many people have them.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

The finding

Laron and Werner state the epidemiological observation directly: patients with Laron syndrome, described as the best-characterised condition among the congenital IGF-1 deficiencies, do not develop cancer. They describe this evasion as emphasising the central role of the growth hormone and IGF-1 system in cancer biology.

Why the mechanism is plausible rather than surprising

IGF-1 is a growth factor. Its signalling promotes cell proliferation and opposes programmed cell death, both processes cancer depends on. A lifelong reduction in that signalling would be expected to reduce the probability of a cell accumulating the changes required to become malignant, and the observation matches the prediction.

What the authors did next

Genome-wide profiling of cells from Laron syndrome patients against normal controls, using immortalised lymphoblastoid lines, to identify differentially expressed genes that might provide a biological foundation for the protection. That moves the work from an epidemiological observation toward a mechanism, which is the necessary next step.

The limits of a rare-condition observation

Laron syndrome cohorts are small, and absence of an event in a small group is weaker evidence than its presence would be. The affected individuals also differ from the general population in more ways than IGF-1 alone. The finding is striking and it is an observation in a rare population, not a controlled comparison.

Frequently asked questions

What causes Laron syndrome?

A growth hormone receptor defect. Growth hormone is produced but cannot be received, so the liver does not produce IGF-1 normally.

What did Laron and Werner report?

That patients with the syndrome do not develop cancer, which they describe as emphasising the central role of the GH-IGF-1 system in cancer biology.

How strong is that evidence?

Striking but limited: cohorts are small, absence of an event is weaker than its presence, and affected individuals differ in more ways than IGF-1 alone.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.